Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases (STEREO-OS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03143322
Recruitment Status : Recruiting
First Posted : May 8, 2017
Last Update Posted : February 22, 2022
National Cancer Institute, France
Information provided by (Responsible Party):

Brief Summary:

Bone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer. Breast, prostate, and lung cancers are responsible for 70% of bone metastases. Cancer with bone metastases compared to other metastatic sites is considered as associated with a better prognosis, particularly for breast and prostate cancer. Bone metastases may be present at diagnosis (synchronous metastasis) or appear at a later time (metachronous metastasis).

The concept of "oligometastases" was proposed in patients with about 3 up to 5 metastases (without restriction on the primary site) and associated with an intermediate prognosis. It was hypothesized that local treatment with curative intent, aiming at the few metastatic sites, would yield long-term survival probabilities, along with systemic therapies.

Long-term survivors have been reported after curative-intent treatment of metastasis in sarcoma and colorectal cancers with liver or lung metastasis. We chose to focus on bone metastasis because of their high incidence, their impact on the patient's quality of life and autonomy, and their accessibility to potentially curative radiotherapy.

The systemic treatment of metastatic cancer includes hormonal therapy (breast and prostate cancer), biologically-targeted drugs and chemotherapy (all cancers).

Stereotactic radiotherapy is a highly accurate technique was initially developed for performing the radiosurgery of brain tumors in patients for whom it was deemed be too difficult to proceed to classical excision surgery. In this process, a high total dose of radiation is delivered in a single fraction to a well-defined intra-cranial target. The concept of radiotherapy in stereotactic conditions was extended to one or several fractions delivered to small volumes primary tumors/ metastases in extra-cranial sites (Stereotactic Body RadioTherapy [SBRT]). At present, high control rates have been achieved for lung metastases. Similarly, very high local control rates have been reported in bone metastases after stereotactic radiotherapy.

In this protocol, our purpose is to demonstrate, via a randomized phase III trial, that high doses of radiotherapy, delivered in stereotactic conditions to the bone metastases (between 1 and 3 metastases) in solid tumor patients is able to improve the survival without progression.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Metastatic Lung Cancer Metastatic Prostate Cancer Bone Metastases Radiation: SBRT Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 196 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extracranial Stereotactic Body Radiation Therapy (SBRT) Added to Standard Treatment Versus Standard Treatment Alone in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases
Actual Study Start Date : January 24, 2018
Estimated Primary Completion Date : January 24, 2026
Estimated Study Completion Date : July 24, 2027

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Systemic treatment + SBRT
Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
Radiation: SBRT
SBRT will be added to systemic (standard) treatment of bone metastases.

No Intervention: Systemic treatment
Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 1 year ]
    To evaluate the impact of SBRT on Progression-Free Survival (PFS) at 1 year according to RECIST 1.1 and PERCIST 1.0 Criteria

Secondary Outcome Measures :
  1. PFS at 2 and 3 years [ Time Frame: 2 years and 3 years after treatment ]
    Progression-Free Survival (PFS) at 2 and 3 years will be evaluated according to RECIST 1.1 and PERCIST

  2. Bone progression free survival at 1, 2 and 3 years [ Time Frame: 1, 2 and 3 years after treatment ]
    Distant bone progression at 2 and 3 years will be evaluated according to RECIST Criteria 1.1 and at 1 year according to RECIST Criteria 1.1 and PERCIST

  3. Local control at 1, 2 and 3 years [ Time Frame: 1, 2 and 3 years after treatment ]
    Local control will be evaluated at 1, 2 and 3 years according to RECIST Criteria 1.1 and PERCIST

  4. Cancer-specific survival [ Time Frame: 1, 2 and 3 years after treatment ]
  5. Overall survival [ Time Frame: 1, 2 and 3 years after treatment ]
  6. SBRT toxicities [ Time Frame: 1, 2 and 3 years after treatment ]
    according CTCAE 4.0 scale

  7. Patient's Quality of life [ Time Frame: at baseline, 6 weeks after randomization, and 3 months, 6 months and 1, 2 and 3 years after treatment ]
    self-administered questionnaire

  8. Pain score [ Time Frame: at baseline, once a week during 2 weeks and 6 weeks after randomization, and at 3 months, 6 months and 1, 2 and 3 years after treatment ]
    according to Numeric Scale related to pain medication

  9. Cost utility [ Time Frame: 6 weeks after randomization ]
    QALYs (Quality-Adjusted Life Years) and ICERs (Incremental Cost-Effectiveness Ratios) calculation based on EQ-5D-3L questionnaire.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients older than 18 years and younger than 75 years
  2. Good general condition: WHO performance status ≤1
  3. Patients with histological proof of breast, non-small cell lung, or prostate cancer
  4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery
  5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases
  6. Patients with between 1 and 3 synchronous or metachronous bone metastases as defined by NaF-PET and spinal MRI (if necessary)
  7. Bones metastases treatable by SBRT
  8. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy
  9. Patients who have received the information sheet, dated and signed the informed consent form
  10. Affiliated to the social security system

Exclusion Criteria:

  1. Visceral metastases as defined by FDG-PET (or F-Choline-PET for prostate cancer) and cerebral CT or MRI performed within six weeks before SBRT
  2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate cancer patients remain eligible if hormonal treatment was initiated before enrollment
  3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture…)
  4. More than 3 bone metastases as defined by NaF-PET and spinal MRI (if spinal bone metastases on NaF-PET)
  5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix)
  6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy)
  7. Patient enrolled in another therapeutic trial
  8. Pregnant women or breast feeding mothers,
  9. Hypersensitivity to the active substance (FDG and NaF or F-Choline for prostate cancer) or to any of the excipients
  10. Contraindication to MRI
  11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03143322

Layout table for location contacts
Contact: Marie Bergeaud, PhD +33(0) 1 73 77 54 38

Show Show 23 study locations
Sponsors and Collaborators
National Cancer Institute, France
Layout table for investigator information
Principal Investigator: Sebastien Thureau, MD Centre Henri Becquerel
Principal Investigator: Jean-Christophe Faivre, MD Institut de Cancérologie de Lorraine - Alexis Vautrin
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: UNICANCER Identifier: NCT03143322    
Other Study ID Numbers: UC-0107/1603
First Posted: May 8, 2017    Key Record Dates
Last Update Posted: February 22, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UNICANCER:
Bone-only metastases
solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes